Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks

被引:15
作者
Bangalore, Sripal [1 ]
Ogedegbe, Gbenga [2 ,3 ]
Gyamfi, Joyce [2 ]
Guo, Yu [2 ]
Roy, Jason [4 ]
Goldfeld, Keith [2 ]
Torgersen, Christopher [2 ]
Capponi, Louis [5 ,6 ]
Phillips, Christopher [7 ]
Shah, Nirav R. [8 ]
机构
[1] NYU, Sch Med, Leon H Charney Div Cardiol, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA
[3] NYU, Global Inst Publ Hlth, New York, NY 10016 USA
[4] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[5] New York City Hlth & Hosp Cooperat, New York, NY USA
[6] NYU, Sch Med, Dept Med, New York, NY 10016 USA
[7] Morehouse Sch Med, Atlanta, GA 30310 USA
[8] Kaiser Fdn Hosp & Hlth Plan, Pasadena, CA USA
基金
美国国家卫生研究院; 美国医疗保健研究与质量局;
关键词
Angiotensin-converting enzyme inhibitors; Blacks; Hypertension; PROPENSITY SCORE; AFRICAN-AMERICAN; HEART-FAILURE; CLINICAL-TRIALS; KIDNEY-DISEASE; BLOOD-PRESSURE; RISK; HYDROCHLOROTHIAZIDE; AMLODIPINE; MANAGEMENT;
D O I
10.1016/j.amjmed.2015.04.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Angiotensin-converting enzyme inhibitors are used widely in the treatment of patients with hypertension. However, their efficacy in hypertensive blacks when compared with other antihypertensive agents is not well established. METHODS: We performed a cohort study of patients using data from a clinical data warehouse of 434,646 patients from New York City's Health and Hospitals Corporation from January 2004 to December 2009. Patients were divided into the following comparison groups: angiotensin-converting enzyme inhibitors vs calcium channel blockers, angiotensin-converting enzyme inhibitors vs thiazide diuretics, and angiotensin-converting enzyme inhibitors vs beta-blockers. The primary outcome was a composite of death, myocardial infarction, and stroke. Secondary outcomes included the individual components and heart failure. RESULTS: In the propensity score-matched angiotensin-converting enzyme inhibitors vs calcium channel blocker comparison cohort (4506 blacks in each group), angiotensin-converting enzyme inhibitors were associated with a higher risk of primary outcome (hazard ratio [HR], 1.45; 95% confidence interval [CI], 1.19-1.77; P = .0003), myocardial infarction (HR, 3.40; 95% CI, 1.25-9.22; P = .02), stroke (HR, 1.82; 95% CI, 1.29-2.57; P = .001), and heart failure (HR, 1.77; 95% CI, 1.30-2.42; P = .0003) when compared with calcium channel blockers. For the angiotensin-converting enzyme inhibitors vs thiazide diuretics comparison (5337 blacks in each group), angiotensin-converting enzyme inhibitors were associated with a higher risk of primary outcome (HR, 1.65; 95% CI, 1.33-2.05; P<.0001), death (HR, 1.35; 95% CI, 1.03-1.76; P = .03), myocardial infarction (HR, 4.00; 95% CI, 1.34-11.96; P = .01), stroke (HR, 1.97; 95% CI, 1.34-2.92; P = .001), and heart failure (HR, 3.00; 95% CI, 1.99-4.54; P<.0001). For the angiotensin-converting enzyme inhibitors vs beta-blocker comparison, the outcomes between the groups were not significantly different. CONCLUSIONS: In a real-world cohort of hypertensive blacks, angiotensin-converting enzyme inhibitors were associated with a higher risk of cardiovascular events when compared with calcium channel blockers or thiazide diuretics. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:1195 / 1203
页数:9
相关论文
共 50 条
  • [41] The Evolution of Renin-Angiotensin Blockade: Angiotensin-Converting Enzyme Inhibitors as the Starting Point
    Sica, Domenic A.
    CURRENT HYPERTENSION REPORTS, 2010, 12 (02) : 67 - 73
  • [42] Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer
    Helgeson, Scott A.
    Waddle, Mark R.
    Burnside, Rebecca C.
    Debella, Yalew T.
    Lee, Augustine S.
    Burger, Charles D.
    Li, Zhuo
    Johnson, Patrick W.
    Patel, Neal M.
    SOUTHERN MEDICAL JOURNAL, 2021, 114 (09) : 607 - 613
  • [43] Angiotensin-Converting Enzyme Inhibitors and Bacterial Pneumonia in Patients with Parkinson Disease
    Wang, Han-Cheng
    Lin, Che-Chen
    Lau, Chi-Ieong
    Chang, Anna
    Kao, Chia-Hung
    MOVEMENT DISORDERS, 2015, 30 (04) : 593 - 596
  • [44] 3D-QSAR studies on angiotensin-converting enzyme (ACE) inhibitors: a molecular design in hypertensive agents
    San Juan, AA
    Cho, SJ
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2005, 26 (06) : 952 - 958
  • [45] Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users
    de Jong, Hilda J. I.
    Vandebriel, Rob J.
    Saldi, Siti R. F.
    van Dijk, Liset
    van Loveren, Henk
    Tervaert, Jan Willem Cohen
    Klungel, Olaf H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (08) : 835 - 843
  • [46] Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis
    Borghi, Claudio
    Levy, Bernard, I
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (04) : 815 - 826
  • [47] Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis
    Chang, Tara I.
    Shilane, David
    Brunelli, Steven M.
    Cheung, Alfred K.
    Chertow, Glenn M.
    Winkelmayer, Wolfgang C.
    AMERICAN HEART JOURNAL, 2011, 162 (02) : 324 - 330
  • [48] Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials
    Fan Shunan
    Yuan Jiqing
    Dong Xue
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2018, 19 (04)
  • [49] Effect of antihypertensive therapy with angiotensin-converting enzyme inhibitors on chronic periodontitis: a case-control study
    Rodrigues, M.
    Barbirato, D.
    Luiz, R. R.
    Scharfstein, J.
    Salles, G. F.
    Feres-Filho, E. J.
    ORAL DISEASES, 2016, 22 (08) : 791 - 796
  • [50] Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure
    O'Toole, L
    Stewart, M
    Padfield, P
    Channer, K
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (06) : 988 - 994